在过去的二十年中，节拍化疗引起了相当大的关注，并在癌症治疗中取得了显着的成功。通过长期给药和低剂量方案，节拍化疗可减少不良事件，但仍能有效控制疾病。其抗血管生成特性、对癌细胞的直接影响、对肿瘤微环境的免疫调节作用以及代谢重编程能力的鉴定确立了这种治疗方法的内在多靶点性质。最近，节拍化疗的使用已经从转移性疾病的挽救治疗发展到高危癌症患者的辅助维持治疗，这是由几项实质性 III 期试验的成功推动的。在这篇综述中，我们深入研究了节拍化疗抗肿瘤作用的机制，并提供了与其他疗法联合治疗各种恶性肿瘤的见解。此外，我们还讨论了这种治疗方案的健康经济优势和候选者。© 作者。

Over the past two decades, metronomic chemotherapy has gained considerable attention and has demonstrated remarkable success in the treatment of cancer. Through chronic administration and low-dose regimens, metronomic chemotherapy is associated with fewer adverse events but still effectively induces disease control. The identification of its antiangiogenic properties, direct impact on cancer cells, immunomodulatory effects on the tumour microenvironment, and metabolic reprogramming ability has established the intrinsic multitargeted nature of this therapeutic approach. Recently, the utilization of metronomic chemotherapy has evolved from salvage treatment for metastatic disease to adjuvant maintenance therapy for high-risk cancer patients, which has been prompted by the success of several substantial phase III trials. In this review, we delve into the mechanisms underlying the antitumour effects of metronomic chemotherapy and provide insights into potential combinations with other therapies for the treatment of various malignancies. Additionally, we discuss health-economic advantages and candidates for the utilization of this treatment option.© The author(s).